Balanced news tone
News Sentiment
ADAG sentiment intelligence
Adagene Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
76/100 classification confidence.
directly relevant articles
high-authority source matches
-11.9% over one week, +10.4% over four weeks, trend active, and materially above fair value.
Guggenheim reiterates Adagene stock Buy rating on competitor shift
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Adagene Inc. (ADAG) Q2 2025 Earnings: EPS Misses Estimates Amid R&D Progress - Guidance Update
- Tone
- Negative 15/100
- Event
- Earnings
- Published
- 24 May 2026 07:00
- Source
- dars.gov.et
12 Health Care Stocks Moving In Thursday's After-Market Session
This article lists 12 healthcare stocks that experienced significant movement in Thursday's after-market session. It highlights both gainers, such as Akari Therapeutics and BioNTech, and losers, including NervGen Pharma and Adagene, along with their respective percentage changes
- Tone
- Negative 33/100
- Event
- Market update
- Published
- 21 May 2026 21:09
- Source
- Benzinga
WuXi entities report 3.49M-share stake in Adagene (NASDAQ: ADAG)
WuXi PharmaTech Healthcare Fund I L.P. and its parent, WuXi AppTec Co., Ltd., have reported beneficial ownership of 3,485,038 ordinary shares in Adagene Inc. (NASDAQ: ADAG), equivalent to 2,788,030 American Depositary Shares (ADS), amounting to a 5.9% stake. This information was
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 15 May 2026 20:10
- Source
- Stock Titan
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Adagene to Participate in Two Upcoming Investor Conferences
Adagene Inc. (Nasdaq: ADAG) announced that its senior management will participate in two upcoming investor conferences: the Stifel Annual Virtual Oncology Event on May 19-20, 2026, and the Jefferies LLC Global Healthcare Conference from June 2-4, 2026. The company will hold one-o
- Tone
- Positive 70/100
- Event
- Market update
- Published
- 12 May 2026 12:09
- Source
- GlobeNewswire
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Adagene (ADAG) Partners With Incyte (INCY) to Evaluate Combination Therapy for Colorectal Cancer
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Apr 2026 14:15
- Source
- Insider Monkey
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Apr 2026 20:01
- Source
- GlobeNewswire
Adagene Presents Two Posters at AACR 2026 with New Data
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Apr 2026 07:00
- Source
- GlobeNewswire
Adagene Looks Attractive With ADG126 And Validating Partnerships (NASDAQ:ADAG)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Apr 2026 07:00
- Source
- Seeking Alpha
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Apr 2026 07:00
- Source
- Market source
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 01 Apr 2026 07:00
- Source
- GlobeNewswire
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Adagene (ADAG) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Apr 2025 00:35
- Source
- Stock Titan
Adagene Stock Price Forecast. Should You Buy ADAG?
- Tone
- Positive 66/100
- Event
- Guidance
- Published
- 16 Feb 2021 07:29
- Source
- StockInvest.us
Should I buy Adagene (ADAG)
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 13 Feb 2021 07:14
- Source
- Zacks Investment Research